Page last updated at 09:33 GMT, Sunday, 4 October 2009 10:33 UK

'Promising results' from MS drug

Five patients taking part in a trial for a new drug for multiple sclerosis (MS) have seen "promising results", health officials have said.

The Norfolk and Norwich University Hospital is one of four centres in England taking part in the study.

Neurology research nurse Donna Clements said the patients have the relapsing-remitting form of the disease.

Since starting the trial two years ago, their rate of relapse has reduced significantly, she said.

MS is a neurological condition that affects the transfer of messages from the central nervous system to the rest of the body.

Ms Clements said: "All the patients involved in the study have the relapsing-remitting form of the disease and all were suffering relapses at least once a year before they started the clinical trial two years ago.

"Since then their rate of relapse has reduced significantly and some patients have not had any relapses at all."

Leading the study in Norfolk is consultant neurologist Dr Martin Lee, who is soon beginning a similar study for patients with primary-progressive MS, the most aggressive form of the disease.



Print Sponsor


SEE ALSO
Test 'pinpoints MS progression'
08 Dec 03 |  Health
Stem cells trial for MS patients
26 Sep 07 |  Bristol
Drug may reverse MS brain damage
23 Oct 08 |  Health

RELATED INTERNET LINKS
The BBC is not responsible for the content of external internet sites


FEATURES, VIEWS, ANALYSIS
Has China's housing bubble burst?
How the world's oldest clove tree defied an empire
Why Royal Ballet principal Sergei Polunin quit

BBC navigation

BBC © 2014 The BBC is not responsible for the content of external sites. Read more.

This page is best viewed in an up-to-date web browser with style sheets (CSS) enabled. While you will be able to view the content of this page in your current browser, you will not be able to get the full visual experience. Please consider upgrading your browser software or enabling style sheets (CSS) if you are able to do so.

Americas Africa Europe Middle East South Asia Asia Pacific